Survey of complications of indocyanine green angiography in Japan

A. Obana, T. Miki, K. Hayashi, M. Takeda, A. Kawamura, T. Mutoh, S. Harino, I. Fukushima, H. Komatsu, Y. Takaku, Fumio Shiraga, H. Matsuhashi, Y. Torii, N. Masaoka, T. Kondoh, Y. Hasegawa

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography. METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera. RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992. Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions. For three patients, the decision was made not to proceed with angiography after positive preangiographic testing. The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is as safe as fluorescein for use in angiography.

Original languageEnglish
Pages (from-to)749-753
Number of pages5
JournalAmerican Journal of Ophthalmology
Volume118
Issue number6
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Indocyanine Green
Angiography
Japan
Fluorescein
Surveys and Questionnaires
Exanthema
Hypotension
Nausea
Veins
Shock
Therapeutics
Safety
Pain

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Obana, A., Miki, T., Hayashi, K., Takeda, M., Kawamura, A., Mutoh, T., ... Hasegawa, Y. (1994). Survey of complications of indocyanine green angiography in Japan. American Journal of Ophthalmology, 118(6), 749-753.

Survey of complications of indocyanine green angiography in Japan. / Obana, A.; Miki, T.; Hayashi, K.; Takeda, M.; Kawamura, A.; Mutoh, T.; Harino, S.; Fukushima, I.; Komatsu, H.; Takaku, Y.; Shiraga, Fumio; Matsuhashi, H.; Torii, Y.; Masaoka, N.; Kondoh, T.; Hasegawa, Y.

In: American Journal of Ophthalmology, Vol. 118, No. 6, 1994, p. 749-753.

Research output: Contribution to journalArticle

Obana, A, Miki, T, Hayashi, K, Takeda, M, Kawamura, A, Mutoh, T, Harino, S, Fukushima, I, Komatsu, H, Takaku, Y, Shiraga, F, Matsuhashi, H, Torii, Y, Masaoka, N, Kondoh, T & Hasegawa, Y 1994, 'Survey of complications of indocyanine green angiography in Japan', American Journal of Ophthalmology, vol. 118, no. 6, pp. 749-753.
Obana A, Miki T, Hayashi K, Takeda M, Kawamura A, Mutoh T et al. Survey of complications of indocyanine green angiography in Japan. American Journal of Ophthalmology. 1994;118(6):749-753.
Obana, A. ; Miki, T. ; Hayashi, K. ; Takeda, M. ; Kawamura, A. ; Mutoh, T. ; Harino, S. ; Fukushima, I. ; Komatsu, H. ; Takaku, Y. ; Shiraga, Fumio ; Matsuhashi, H. ; Torii, Y. ; Masaoka, N. ; Kondoh, T. ; Hasegawa, Y. / Survey of complications of indocyanine green angiography in Japan. In: American Journal of Ophthalmology. 1994 ; Vol. 118, No. 6. pp. 749-753.
@article{e00aa7278d534ec7815196172ec178a6,
title = "Survey of complications of indocyanine green angiography in Japan",
abstract = "PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography. METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera. RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992. Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions. For three patients, the decision was made not to proceed with angiography after positive preangiographic testing. The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34{\%}), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is as safe as fluorescein for use in angiography.",
author = "A. Obana and T. Miki and K. Hayashi and M. Takeda and A. Kawamura and T. Mutoh and S. Harino and I. Fukushima and H. Komatsu and Y. Takaku and Fumio Shiraga and H. Matsuhashi and Y. Torii and N. Masaoka and T. Kondoh and Y. Hasegawa",
year = "1994",
language = "English",
volume = "118",
pages = "749--753",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Survey of complications of indocyanine green angiography in Japan

AU - Obana, A.

AU - Miki, T.

AU - Hayashi, K.

AU - Takeda, M.

AU - Kawamura, A.

AU - Mutoh, T.

AU - Harino, S.

AU - Fukushima, I.

AU - Komatsu, H.

AU - Takaku, Y.

AU - Shiraga, Fumio

AU - Matsuhashi, H.

AU - Torii, Y.

AU - Masaoka, N.

AU - Kondoh, T.

AU - Hasegawa, Y.

PY - 1994

Y1 - 1994

N2 - PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography. METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera. RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992. Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions. For three patients, the decision was made not to proceed with angiography after positive preangiographic testing. The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is as safe as fluorescein for use in angiography.

AB - PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography. METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera. RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992. Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions. For three patients, the decision was made not to proceed with angiography after positive preangiographic testing. The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is as safe as fluorescein for use in angiography.

UR - http://www.scopus.com/inward/record.url?scp=0028034726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028034726&partnerID=8YFLogxK

M3 - Article

VL - 118

SP - 749

EP - 753

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 6

ER -